Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study to Evaluate LIFE-001
Sponsor: LifeMine Therapeutics
Summary
The goal of this clinical trial is to learn if LIFE-001 is safe and tolerable for healthy adult volunteers.
Official title: A Phase I, Single Ascending and Multiple Ascending Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LIFE-001
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2025-04-07
Completion Date
2026-11-13
Last Updated
2026-07-07
Healthy Volunteers
Yes
Conditions
Interventions
LIFE-001
Single dose of LIFE-001 between 10mg and up to 1500mg administered subcutaneously
Placebo
Single dose of placebo comparator administered subcutaneously
LIFE-001 MAD
Four doses of LIFE-001 between 50mg and up to 1500mg administered subcutaneously QW or seven doses of LIFE-001 between 50mg and up to 1500mg administered subcutaneously BIW.
Placebo MAD
Four doses of placebo administered subcutaneously QW or seven doses of placebo administered subcutaneously BIW.
Locations (1)
Veritus Research Pty Ltd
Bayswater, Victoria, Australia